Soligenix Inc

NASDAQ:SNGXUnited States

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Contact Information

Headquarters

29 Emmons Drive, Suite B-10PRINCETON, NJ, United States 08540

Phone

609-538-8200

Fax

609-452-6467

Executives

Chairman of the Board, Chief Executive Officer and President

Christopher Schaber

Chief Financial Officer, Senior Vice President, Corporate Secretary

Jonathan Guarino

Senior Vice President, Chief Scientific Officer

Oreola Donini

Senior Vice President and Chief Medical Officer

Richard Straube

Independent Director

Gregg Lapointe